In a lawsuit, Texas Attorney General Ken Paxton alleged that Eli Lilly bribed healthcare providers to prescribe its most profitable drugs, including the GLP-1 agonist tirzepatide (Mounjaro, Zepbound).

A 52-study meta-analysis found that regulated liothyronine (LT3) use was not associated with a higher risk of death or serious adverse outcomes in patients with hypothyroidism. ( Journal of Clinical Endocrinology & Metabolism )

The FDA said it's taking action to protect patients from unapproved animal-derived thyroid medications and expressed concern over the use of unapproved GLP-1 receptor agonists for weight loss, such as fraudulent compounded semaglutide (Ozempic, Wegovy) and tirzepatide.

In related news, Novo Nordisk filed 14 new lawsuits in the U.S. targeting pharmacies p

See Full Page